Abstract
e14085Background: Patients (pts) with recurrent HGGs are usually managed with alkylating chemotherapy +/- bevacizumab. However, prognosis remains poor with an overall survival (OS) of 7-9 months. P...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have